UroGen Pharma Announces Date For ENVISION Data, Long-Term Jelmyto Durability Data, To Be Discussed During Company Sponsored Virtual Event On June 13, 2024
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma Ltd. announced its Q1 2024 financial results and provided updates on its product pipeline, including the ENVISION study for UGN-102 and long-term durability data for Jelmyto. The ENVISION data, to be discussed in a June 13, 2024 virtual event, is expected to support the completion of the NDA for UGN-102 in Q3 2024. Jelmyto showed continued growth with a 10% YoY increase in net sales. A new IND for UGN-103 has been accepted, indicating progress in UroGen's pipeline. The company anticipates UGN-102 could address a $3 billion market opportunity.
May 13, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma announced positive Q1 2024 financial results, showing a 10% YoY growth in Jelmyto sales, and significant progress in its product pipeline with the upcoming ENVISION study data for UGN-102 and acceptance of a new IND for UGN-103. The company highlighted the potential market opportunity for UGN-102 as exceeding $3 billion.
The positive financial results and promising pipeline updates, particularly regarding UGN-102 and UGN-103, suggest a strong short-term outlook for URGN. The anticipated market opportunity for UGN-102 and the growth in Jelmyto sales are likely to be viewed positively by investors, potentially leading to an increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100